Abstract

Introduction: A wide variety of both benign and malignant tumours arise from different components of the renal parenchyma, notably tubular epithelium. Prognostic markers for Renal cell carcinoma such as tumor stage, grade and necrosis are useful for determining appropriate follow-up and selecting patients for adjuvant therapy. We undertook this study to determine the relative frequencies of different types of adult renal tumours, their clinical, radiological, gross morphological and histopathological features. Our second objective was to evaluate these pathological variables and to establish possible correlations between them. Materials and Methods: A Total of 60 Cases of adult renal neoplasms diagnosed at our institute from June 2007 to June 2014 were reviewed. Age, sex, histologic subtype, pT stage, Fuhrman grade, tumor necrosis were determined in all cases. Results: Among 60 patients, 36 were males and 24 were females. Mean age was 46.5 years. 83.3% tumours were malignant and 16.67%, benign. Among malignant tumours, Renal cell carcinoma (RCC) was the commonest(78.3%). Various subtypes of RCC included: conventional/clear cell RCC (73.2%); papillary, (14.6%); chromophobe (2.4%) and RCC unclassified (1.66%). Other malignant tumours were: leiomyosarcoma (1.66%); spindle cell sarcoma (1.66%); primitive neuroectodermal tumour(1.66%). Benign renal tumours included Angiomyolipoma(10%), oncocytoma(1.66%); metanephric adenoma(1.66%) and renomedullary interstitial tumour (1.66%). Conclusions: RCC was the commonest malignant tumor and conventional/clear cell RCC was the most common subtype. Most of the cases in our study were in grade 2 and stage pT3. Papillary RCC was second most common subtype.Tumor necrosis correlates with higher grade and tumor stage. Key Words: Renal cell carcinoma, Furhman nuclear grade, Leiomyosarcoma, renomedullary interstitial tumour, Primitive neuroectodermal tumour

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call